News

“The election of Peter Bambic as the new President and CEO of Adaltis Inc. comes at a very exciting time in the history of the Company, as we

For the fourth quarter of fiscal 2008, revenues were $37.8 million, compared to $40.4 million in the same quarter of fiscal 2007. For the full fiscal year ended

Mr Emmens has been a Vertex director since 2004, and previously served as CEO of Astra Merck, and of Shire, where he continues as chairman. Dr Boger, who

Internationally, the company is in the process of restructuring its sales and marketing business units in four countries in order to eliminate direct selling infrastructure costs. The company

US-based BioMarin Pharmaceutical has received marketing approval from ANVISA, Brazil’s National Health Surveillance Agency, for Naglazyme for the treatment of patients with mucopolysaccharidosis VI. Naglazyme was approved by

“While the economic and capital markets outlook for 2009 remains uncertain, the regenerative medicine and stem cell sectors have gained significant momentum and exposure since the beginning of

Ablynx, a developer of antibody-derived therapeutic proteins, has announced that it will receive milestone payments totaling E3m from Boehringer Ingelheim triggered as part of its strategic alliance for

This decision follows a successful end-of-Phase II meeting with the FDA, held on January 30, 2009. Algeta began enrolling patients for its global Phase III Alsympca study in

As previously reported, 29 of 109 evaluable patients, or 27%, achieved a response as assessed by central independent oncology review, which is the primary endpoint of the trial.